Chugai Pharmaceutical formed an agreement with Singapore-based Gero to co-develop therapies targeting age-related diseases using Gero’s AI-powered target discovery platform and Chugai’s antibody engineering. The deal includes up to $250 million in milestones and royalty payments. Simultaneously, Shanghai’s Mabwell Bioscience expanded its biosimilar footprint by licensing denosumab biosimilars to Philippine firm UNILAB for commercialization. These collaborations exemplify Asia’s growing biotech innovation ecosystem and international integration in both novel therapeutics and biosimilars markets.